EA201490944A1 - Двойной ингибитор met и vegf для лечения рака - Google Patents
Двойной ингибитор met и vegf для лечения ракаInfo
- Publication number
- EA201490944A1 EA201490944A1 EA201490944A EA201490944A EA201490944A1 EA 201490944 A1 EA201490944 A1 EA 201490944A1 EA 201490944 A EA201490944 A EA 201490944A EA 201490944 A EA201490944 A EA 201490944A EA 201490944 A1 EA201490944 A1 EA 201490944A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- double
- met
- cancer treatment
- vegf inhibitor
- vegf
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002525 vasculotropin inhibitor Substances 0.000 title 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557358P | 2011-11-08 | 2011-11-08 | |
| PCT/US2012/064116 WO2013070890A1 (en) | 2011-11-08 | 2012-11-08 | Dual inhibitor of met and vegf for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201490944A1 true EA201490944A1 (ru) | 2014-10-30 |
Family
ID=47179011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490944A EA201490944A1 (ru) | 2011-11-08 | 2012-11-08 | Двойной ингибитор met и vegf для лечения рака |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140323522A1 (enExample) |
| EP (1) | EP2776033A1 (enExample) |
| JP (2) | JP2014532766A (enExample) |
| KR (1) | KR20140088610A (enExample) |
| CN (1) | CN104159585A (enExample) |
| AU (2) | AU2012335737A1 (enExample) |
| BR (1) | BR112014011009A2 (enExample) |
| CA (1) | CA2854336A1 (enExample) |
| EA (1) | EA201490944A1 (enExample) |
| HK (1) | HK1202062A1 (enExample) |
| IL (1) | IL232421A0 (enExample) |
| IN (1) | IN2014CN04067A (enExample) |
| MX (1) | MX2014005458A (enExample) |
| TW (2) | TWI662962B (enExample) |
| WO (1) | WO2013070890A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| HUE057574T2 (hu) | 2011-02-10 | 2022-05-28 | Exelixis Inc | Eljárás kinolin-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények elõállítására |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| TWI610918B (zh) | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
| WO2013043840A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| CN110511158A (zh) | 2011-10-20 | 2019-11-29 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| WO2013166296A1 (en) * | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN105121412B (zh) | 2013-03-15 | 2019-07-12 | 埃克塞里艾克西斯公司 | N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物 |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| EP3177311B1 (en) | 2014-08-05 | 2024-10-30 | Exelixis, Inc. | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| MA44672A (fr) * | 2016-04-15 | 2019-02-20 | Exelixis Inc | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| US10723701B2 (en) * | 2016-10-18 | 2020-07-28 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
| AU2018272088C1 (en) | 2017-05-26 | 2022-09-22 | Exelixis, Inc. | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MA51673B1 (fr) | 2018-01-26 | 2025-10-31 | Exelixis, Inc. | Composés pour le traitement des troubles dépendants de kinases |
| CN113321647B (zh) | 2018-06-15 | 2024-08-27 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| TW202444365A (zh) | 2023-01-31 | 2024-11-16 | 漢達生技醫藥股份有限公司 | 改良之卡博替尼組合物及其使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| PL2392565T3 (pl) | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| DK2621481T4 (da) * | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| JP2013537918A (ja) * | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
-
2012
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en not_active Ceased
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Ceased
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
- 2012-11-08 HK HK15102604.7A patent/HK1202062A1/xx unknown
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2776033A1 (en) | 2014-09-17 |
| CN104159585A (zh) | 2014-11-19 |
| IL232421A0 (en) | 2014-06-30 |
| TW201818937A (zh) | 2018-06-01 |
| BR112014011009A2 (pt) | 2017-06-06 |
| HK1202062A1 (en) | 2015-09-18 |
| MX2014005458A (es) | 2015-04-16 |
| AU2012335737A1 (en) | 2014-06-05 |
| TW201322981A (zh) | 2013-06-16 |
| CA2854336A1 (en) | 2013-05-16 |
| AU2017225103A1 (en) | 2017-09-28 |
| TWI662962B (zh) | 2019-06-21 |
| JP2014532766A (ja) | 2014-12-08 |
| US20140323522A1 (en) | 2014-10-30 |
| WO2013070890A1 (en) | 2013-05-16 |
| IN2014CN04067A (enExample) | 2015-10-23 |
| JP2018048154A (ja) | 2018-03-29 |
| KR20140088610A (ko) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
| EA201390465A1 (ru) | Двойные ингибиторы мэн и фрэс для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| EA201391248A1 (ru) | Биспецифические связывающие агенты | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| BR112013024211A2 (pt) | tratamento de tumores sólidos | |
| CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
| EA201590997A1 (ru) | Соединения и способы их применения | |
| UA110813C2 (uk) | Лікування ліподистрофії | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| IN2014KN00848A (enExample) | ||
| PT2683384E (pt) | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| IL224370B (en) | Combination treatment for prostate carcinoma | |
| HUE048876T2 (hu) | Rákos megbetegedések kezelése | |
| HK1207587A1 (en) | A dual met - vegf modulator for treating osteolytic bone metastases | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| EA201370071A1 (ru) | Способы и композиции для лечения рака легких | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| SMT201600235B (it) | Predittori per il trattamento del cancro | |
| EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
| EA201692534A1 (ru) | Способы лечения гипотонии |